Cargando…

Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma

Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to urothelial carcinoma of the bladder (UCB), upper tract urothelial carcinoma (UTUC) has a higher response rate to ICIs. The stratification...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yuan, Tan, Yezhen, Guan, Bao, Guo, Bin, Xia, Mancheng, Li, Juan, Shi, Yue, Yu, Zihui, Zhang, Qi, Liu, Di, Yang, Xiaopeng, Hao, Junfeng, Gong, Yanqing, Shakeel, Muhammad, Zhou, Liqun, Ci, Weimin, Li, Xuesong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706581/
https://www.ncbi.nlm.nih.gov/pubmed/36451860
http://dx.doi.org/10.7150/thno.77281
_version_ 1784840535514546176
author Liang, Yuan
Tan, Yezhen
Guan, Bao
Guo, Bin
Xia, Mancheng
Li, Juan
Shi, Yue
Yu, Zihui
Zhang, Qi
Liu, Di
Yang, Xiaopeng
Hao, Junfeng
Gong, Yanqing
Shakeel, Muhammad
Zhou, Liqun
Ci, Weimin
Li, Xuesong
author_facet Liang, Yuan
Tan, Yezhen
Guan, Bao
Guo, Bin
Xia, Mancheng
Li, Juan
Shi, Yue
Yu, Zihui
Zhang, Qi
Liu, Di
Yang, Xiaopeng
Hao, Junfeng
Gong, Yanqing
Shakeel, Muhammad
Zhou, Liqun
Ci, Weimin
Li, Xuesong
author_sort Liang, Yuan
collection PubMed
description Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to urothelial carcinoma of the bladder (UCB), upper tract urothelial carcinoma (UTUC) has a higher response rate to ICIs. The stratification of patients most likely to benefit from ICI therapy remains a major clinical challenge. Methods: In this study, we performed the first single-cell RNA sequencing (scRNA-seq) study of 13 surgical tissue specimens from 12 patients with UTUC. The key results were validated by the analysis of two independent cohorts with bulk RNA-seq data for UCB (n = 404) and UTUC (n = 158) and one cohort of patients with metastatic urothelial carcinoma (mUC) who were treated with atezolizumab (n = 348). Results: Using scRNA-seq, we observed a higher proportion of tumor-infiltrating immune cells in locally advanced UTUC. Similar prognostically relevant intrinsic basal and luminal-like epithelial subtypes were found in both UTUC and UCB, although UTUC is predominantly of the luminal subtype. We also discovered that immunosuppressive macrophages and exhausted T-cell subpopulations were enriched in the basal subtype and showed enhanced interactions. Furthermore, we developed a gene expression signature (Macro-C3 score) capturing the immunosuppressive macrophages that better predicts outcomes than the currently established subtypes. We also developed a computational method to model immune evasion, and the Macro-C3 score predicted therapeutic response of mUC treated with first-line anti-PD-L1 inhibitors in patients with lower basal scores. Conclusions: Overall, the distinct microenvironment and Macro-C3 score provide an explanation for ICI efficacy in urothelial carcinoma and reveal new candidate regulators of immune evasion, suggesting potential therapeutic targets for improving antitumor immunity in the basal subtype.
format Online
Article
Text
id pubmed-9706581
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-97065812022-11-29 Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma Liang, Yuan Tan, Yezhen Guan, Bao Guo, Bin Xia, Mancheng Li, Juan Shi, Yue Yu, Zihui Zhang, Qi Liu, Di Yang, Xiaopeng Hao, Junfeng Gong, Yanqing Shakeel, Muhammad Zhou, Liqun Ci, Weimin Li, Xuesong Theranostics Research Paper Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to urothelial carcinoma of the bladder (UCB), upper tract urothelial carcinoma (UTUC) has a higher response rate to ICIs. The stratification of patients most likely to benefit from ICI therapy remains a major clinical challenge. Methods: In this study, we performed the first single-cell RNA sequencing (scRNA-seq) study of 13 surgical tissue specimens from 12 patients with UTUC. The key results were validated by the analysis of two independent cohorts with bulk RNA-seq data for UCB (n = 404) and UTUC (n = 158) and one cohort of patients with metastatic urothelial carcinoma (mUC) who were treated with atezolizumab (n = 348). Results: Using scRNA-seq, we observed a higher proportion of tumor-infiltrating immune cells in locally advanced UTUC. Similar prognostically relevant intrinsic basal and luminal-like epithelial subtypes were found in both UTUC and UCB, although UTUC is predominantly of the luminal subtype. We also discovered that immunosuppressive macrophages and exhausted T-cell subpopulations were enriched in the basal subtype and showed enhanced interactions. Furthermore, we developed a gene expression signature (Macro-C3 score) capturing the immunosuppressive macrophages that better predicts outcomes than the currently established subtypes. We also developed a computational method to model immune evasion, and the Macro-C3 score predicted therapeutic response of mUC treated with first-line anti-PD-L1 inhibitors in patients with lower basal scores. Conclusions: Overall, the distinct microenvironment and Macro-C3 score provide an explanation for ICI efficacy in urothelial carcinoma and reveal new candidate regulators of immune evasion, suggesting potential therapeutic targets for improving antitumor immunity in the basal subtype. Ivyspring International Publisher 2022-11-14 /pmc/articles/PMC9706581/ /pubmed/36451860 http://dx.doi.org/10.7150/thno.77281 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Liang, Yuan
Tan, Yezhen
Guan, Bao
Guo, Bin
Xia, Mancheng
Li, Juan
Shi, Yue
Yu, Zihui
Zhang, Qi
Liu, Di
Yang, Xiaopeng
Hao, Junfeng
Gong, Yanqing
Shakeel, Muhammad
Zhou, Liqun
Ci, Weimin
Li, Xuesong
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
title Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
title_full Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
title_fullStr Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
title_full_unstemmed Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
title_short Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
title_sort single-cell atlases link macrophages and cd8(+) t-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706581/
https://www.ncbi.nlm.nih.gov/pubmed/36451860
http://dx.doi.org/10.7150/thno.77281
work_keys_str_mv AT liangyuan singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT tanyezhen singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT guanbao singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT guobin singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT xiamancheng singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT lijuan singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT shiyue singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT yuzihui singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT zhangqi singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT liudi singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT yangxiaopeng singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT haojunfeng singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT gongyanqing singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT shakeelmuhammad singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT zhouliqun singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT ciweimin singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma
AT lixuesong singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma